Biostatistics and Mathematical Oncology Core Shared Resource ABSTRACT The Biostatistics and Mathematical Oncology Core (BMOC) provides City of Hope Comprehensive Cancer Center (COHCCC) members with access to expert statisticians and mathematicians who collaborate in basic, translational, clinical, and population research. The BMOC staff assist in the development of experimental designs, sample size estimation, statistical computing, data analysis, and interpretation of findings. In collaboration with investigators, they contribute to COHCCC publications and are a resource for new statistical methods in laboratory-based, clinical trial-based, and population-based research. Areas of expertise include: clinical trials; dose-escalation methods; survival analysis; cure models; preclinical studies, assays, bioassays, and toxicity screening; experimental and human genetics; gene expression (e.g., RNA-seq, microarray, NanoString), classification, prediction and signatures; 16s rRNA microbiome taxonomy; longitudinal and functional data analysis; mathematical modeling of cancer; extracting data from 3-dimensional tumor images; epidemiology and observational studies; adaptive questionnaires; SEER, TCGA, and other public databases; and extensive experience in statistics applied to cancer research involving immunology, cellular, and immune- directed therapy, and hematopoietic stem-cell transplantation. The BMOC is directed by Jeffrey Longmate, Ph.D., and draws upon the efforts of 20 faculty and staff who provide a wide range of expertise and play diverse roles in COHCCC research. Major changes have been made to the BMOC since the last review, including the recruitment of Russell Rockne, PhD, to lead a new mathematical oncology service line; the addition of Andrei Rodin, PhD, the Dr. Susumo Ohno Chair in Theoretical Biology; and the recruitment of two statisticians to support the Hematologic Malignancies Program. Operational changes include the appointment of statisticians to Disease Teams and major changes in statistical review procedures for the Protocol Review and Monitoring System. The primary goal of the Core is collaboration, development, and advancement of novel methods in the design, conduct, analysis, and publication of preclinical and clinical cancer-related research. The BMOC provides free short-term consulting to promote early statistical input. During the last finding period, BMOC faculty developed and published novel study designs and data analysis methods, which have been incorporated into Phase I and I/II clinical trials. The BMOC is supported by the Office of Shared Resources and overseen by the BMOC Advisory Committee, which includes the COHCCC Program Leaders. BMOC members work closely with the Integrative Genomics and Bioinformatics Core and the Analytical Pharmacology Core. In the last year, the BMOC supported 401 projects from 117 investigators, including 89 CC members, 48 of whom have peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849202
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609

Showing the most recent 10 out of 1396 publications